Clinic
Memorial Hospital, Albany, N.Y.
Memorial Hospital, Albany, N.Y. was paid $1.31M by Medicaid between Jan 2018 and Sep 2021, across 132 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL, ALBANY, N.Y.
ALBANY, NY 12204
ALBANY, NY 12204
33aNPI1801837539assigned 06/10/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$1.31M
24GClaims43,372
24DCodes billed132
24AFirst – last monthJan 2018 – Sep 2021
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in New York
Rank by total paid#40 of 118
Median peer was paid$372K
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,321 | $30K | |
| 2019 | 40,770 | $1.28M | |
| 2020 | 47 | $347.80 | |
| 2021 | 234 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 1,957 | 1,877 | $221K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 1,812 | 1,738 | $217K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.9% | 810 | 769 | $103K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 251 | 248 | $75K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 4.8% | 141 | 138 | $63K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 642 | 587 | $61K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 1,143 | 380 | $50K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.7% | 343 | 157 | $48K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 240 | 233 | $48K |
| 80053 | Comprehensive metabolic panel | 3.2% | 2,012 | 1,860 | $42K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 405 | 399 | $34K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 131 | 130 | $30K |
120 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 210 | $29K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.0% | 274 | $26K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.8% | 674 | $23K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 84 | $22K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 404 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 149 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 409 | $13K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,613 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 713 | $9K |
| 93975 | <1% | 35 | $9K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 92 | $8K |
| 10060 | <1% | 27 | $8K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 404 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 221 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 611 | $7K |
| 29515 | <1% | 38 | $7K | |
| 93971 | <1% | 56 | $6K | |
| 12001 | <1% | 24 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,140 | $6K |
| 64402 | <1% | 12 | $5K | |
| 97162 | <1% | 41 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 273 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 115 | $4K |
| 76770 | <1% | 12 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 38 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $4K |
| 80348 | <1% | 200 | $3K | |
| 86901 | <1% | 90 | $3K | |
| 29125 | <1% | 16 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 184 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 118 | $3K |
| 76536 | <1% | 29 | $2K | |
| 86900 | <1% | 90 | $2K | |
| 86850 | <1% | 57 | $2K | |
| 81025 | <1% | 657 | $2K | |
| 97035 | <1% | 143 | $2K | |
| 97165 | <1% | 25 | $2K | |
| 97010 | <1% | 99 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 205 | $1K |
| 90715 | <1% | 51 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 42 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,016 | $1K |
| 90682 | <1% | 37 | $994.83 | |
| 86701 | <1% | 96 | $909.59 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 28 | $909.13 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,013 | $891.82 |
| 80061 | Lipid panel | <1% | 137 | $878.03 |
| 36416 | <1% | 283 | $860.46 | |
| 76870 | <1% | 12 | $852.72 | |
| 82043 | <1% | 145 | $741.91 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 801 | $731.93 |
| 73564 | <1% | 91 | $730.01 | |
| 84439 | <1% | 85 | $688.48 | |
| 90686 | <1% | 28 | $686.63 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 88 | $663.59 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $622.09 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,353 | $614.89 |
| 94760 | <1% | 5,155 | $582.40 | |
| 97760 | <1% | 21 | $550.84 | |
| 81003 | <1% | 932 | $476.20 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 23 | $456.54 |
| 76641 | <1% | 14 | $416.77 | |
| 82570 | <1% | 133 | $392.87 | |
| 71045 | Radiologic examination, chest; single view | <1% | 102 | $318.44 |
| 73030 | <1% | 82 | $317.78 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 720 | $306.52 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 681 | $303.61 |
| 85610 | <1% | 97 | $275.45 | |
| 73630 | <1% | 114 | $218.15 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 147 | $217.56 |
| 73130 | <1% | 60 | $164.72 | |
| 83735 | <1% | 213 | $113.43 | |
| 81001 | <1% | 714 | $110.79 | |
| 73610 | <1% | 64 | $108.87 | |
| 87660 | <1% | 261 | $69.85 | |
| 87510 | <1% | 262 | $69.85 | |
| 87480 | <1% | 261 | $69.85 | |
| 83690 | <1% | 638 | $63.12 | |
| 84702 | <1% | 108 | $61.68 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 28 | $57.62 |
| 73110 | <1% | 16 | $57.50 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 36 | $55.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 276 | $53.56 |
| 94664 | <1% | 356 | $51.87 | |
| 74018 | <1% | 12 | $50.00 | |
| 73502 | <1% | 13 | $45.11 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 286 | $45.00 |
| 86618 | <1% | 12 | $37.66 | |
| 84703 | <1% | 414 | $33.58 | |
| 85027 | <1% | 13 | $31.90 | |
| 82947 | <1% | 178 | $29.94 | |
| 87186 | <1% | 90 | $25.83 | |
| 80320 | <1% | 70 | $20.00 | |
| 84484 | <1% | 400 | $17.56 | |
| 83605 | <1% | 106 | $9.30 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 64 | $9.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 245 | $8.57 |
| 87040 | <1% | 46 | $8.15 | |
| 87070 | <1% | 14 | $6.01 | |
| 87077 | <1% | 80 | $5.66 | |
| 87205 | <1% | 13 | $5.54 | |
| J2704 | Injection, propofol, 10 mg | <1% | 267 | $5.35 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 724 | $4.26 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 228 | $3.64 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 38 | $2.83 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 239 | $2.23 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 252 | $1.65 |
| S0028 | Injection, famotidine, 20 mg | <1% | 115 | $1.07 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 251 | $0.32 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 219 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 15 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 13 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 42 | $0.00 |
| 87088 | 0% | 85 | $0.00 | |
| 85379 | 0% | 52 | $0.00 | |
| 96376 | 0% | 103 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 154 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 26 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 164 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANTOS, LORI (CFO)
Parent organizationMEMORIAL HOSPITAL, ALBANY, N.Y.
| Provider | Location | Paid |
|---|---|---|
| Memorial Hospital, Albany, N.Y. | Albany, NY | $608K |
| Burdett Care Center, INC | Troy, NY | $95K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.